| Thyroid hormone therapy for obesity and nonthyroidal illnesses: a systematic review. | |
| | |
MedLine Citation:
|
PMID: 19737920 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
CONTEXT: Thyroid hormone therapy to enhance weight loss in obesity during caloric deprivation and to improve morbidity and mortality in adults with nonthyroidal illnesses remains controversial. OBJECTIVE: The aim of this study was to conduct a systematic review evaluating effectiveness and risks of T(3) and/or T(4) therapy in these populations. DATA SOURCES: Electronic databases and reference lists were searched. STUDY SELECTION: Studies with comparable control groups comparing T(3) and/or T(4) therapy to placebo in randomized controlled trials (RCTs) or prospective observational studies were selected. DATA EXTRACTION: Three reviewers performed serial abstraction. DATA SYNTHESIS: During caloric deprivation of obese subjects, T(3) therapy decreased serum TSH and T(4) concentrations. Consistent effects of T(3) or T(4) on weight loss, protein breakdown, metabolic rate, and heart rate could not be established. In euthyroid cardiac patients, T(3) decreased TSH and free T(4) levels, without consistent effects of T(3) or T(4) on heart rate, cardiac output, or systemic vascular resistance. Mortality increased 3.3-fold with T(4) therapy in acute renal failure patients, whereas an effect in cardiac, critically ill, and burn patients could not be established. Equivalence testing indicated that larger RCTs are required to determine whether thyroid hormone therapy alters end-points in obesity or nonthyroidal illnesses. LIMITATIONS: Numbers of usable unique studies were small, numbers of patients in each study were inadequate, end-points were variable, few RCTs were performed, and study quality of non-RCTs was poor. CONCLUSIONS: Available data are inconclusive regarding effectiveness of thyroid hormone therapy in treating obesity or nonthyroidal illnesses, whereas data support that such therapy induces subclinical hyperthyroidism. |
| | |
Authors:
|
Elaine M Kaptein; Elizabeth Beale; Linda S Chan |
Publication Detail:
|
Type: Journal Article; Review Date: 2009-09-08 |
Journal Detail:
|
Title: The Journal of clinical endocrinology and metabolism Volume: 94 ISSN: 1945-7197 ISO Abbreviation: J. Clin. Endocrinol. Metab. Publication Date: 2009 Oct |
Date Detail:
|
Created Date: 2009-10-07 Completed Date: 2009-10-20 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0375362 Medline TA: J Clin Endocrinol Metab Country: United States |
Other Details:
|
Languages: eng Pagination: 3663-75 Citation Subset: AIM; IM |
Affiliation:
|
Department of Medicine, University of Southern California, Los Angeles, California 90033, USA. ekaptein@usc.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Anti-Obesity Agents / administration & dosage, blood, therapeutic use* Basal Metabolism Caloric Restriction Female Heart Rate Humans Male Middle Aged Obesity / drug therapy* Observation Randomized Controlled Trials as Topic Research Design Thyroxine / administration & dosage, blood, therapeutic use* Treatment Outcome Triiodothyronine / administration & dosage, blood, therapeutic use* Weight Loss / drug effects* |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Obesity Agents; 6893-02-3/Triiodothyronine; 7488-70-2/Thyroxine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Blimp-1/Prdm1 alternative promoter usage during mouse development and plasma cell differentiation.
Next Document: Update in primary aldosteronism.